Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.24, in-line with the analyst estimate of $0.24. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $52.1 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.